A Periodic Safety Update Report (PSUR) is a pharmacovigilance document submitted by pharmaceutical companies to regulatory authorities at defined time points after a drug’s authorization. It provides a comprehensive analysis of the risk-benefit balance of a medicinal product, taking into account new or emerging safety information in the context of cumulative information on benefits and risks.
PSURs are crucial for ongoing safety monitoring and evaluation of marketed drugs. They include summaries of safety data from clinical trials, post-marketing surveillance, and scientific literature, as well as an integrated benefit-risk evaluation to ensure the continued safe and effective use of the product.
PSURs are essential in clinical research as they provide a systematic approach to post-marketing safety surveillance of medicinal products. They allow regulatory authorities and pharmaceutical companies to continuously monitor and evaluate the safety profile of drugs throughout their lifecycle, ensuring that any new risks or changes in known risks are promptly identified and addressed.
The importance of PSURs extends beyond individual products, contributing to the overall safety of public health. By aggregating and analyzing safety data from various sources, PSURs help in detecting rare adverse events, identifying potential safety signals, and facilitating timely regulatory actions or updates to product information, thereby enhancing patient safety and improving the benefit-risk profile of medicines.
We’re pleased to announce a strategic partnership between Axcellant and Prometheus MedTech.AI — a medtech startup developing AI-powered solutions for…
The Axcellant team has returned from the European Association of Nuclear Medicine (EANM) Annual Congress in Barcelona — and it’s…
The robust development of nuclear medicine depends on the availability of radioactive isotopes, some of which are used for diagnostic…
Copyright @ 2025 Axcellant